Aktuellt
SENASTE
Redeye's immediate take on Nanologica's year-end report is relatively undramatic. While sales and profitability were softer than we had estimated, the report signals improving production, which remains a key parameter for the company's outlook. We anticipate maintaining our fair value range.
LÄS MER
